Therapy Detail

Therapy Name AZD2811
Therapy Description

AZD2811 is nanoparticle formulation of Barasertib (AZD1152), which inhibits Aurora kinase B to induce cell cycle arrest and results in tumor regression (PMID: 26865565, PMID: 28292940).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
AZD2811 Aurkb Inhibitors 17 AZD2811 is nanoparticle formulation of Barasertib (AZD1152), which inhibits Aurora kinase B to induce cell cycle arrest and results in tumor regression (PMID: 26865565, PMID: 28292940).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown acute myeloid leukemia not applicable AZD2811 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with AZD2811 nanoparticles resulted in tumor regression in acute myeloid leukemia xenograft models (PMID: 28292940). 28292940
Unknown unknown colon cancer not applicable AZD2811 Preclinical - Cell line xenograft Actionable In a preclinical study, treatment with AZD2811 nanoparticles resulted in tumor regression in colon cancer xenograft models (PMID: 26865565). 26865565
Clinical Trial Phase Therapies Title Recruitment Status
NCT03217838 Phase Ib/II AZD2811 Safety, Tolerability, and Efficacy of AZD2811 Nanoparticles in Patients With Relapsed AML/High-Risk Myelodysplastic Syndrome or Treatment-Naïve Patients. Recruiting
NCT02579226 Phase I Irinotecan AZD2811 A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors Recruiting